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Phase I dose-escalation trials with more than one dosing regimen
Burak Kürsad Günhan,1 2 Sebastian Weber,3 Abdelkader Seroutou,3 Tim Friede1
Traditionally, phase I dose-escalation oncology trials are designed to find a dose at which an ac-
ceptable event rate of dose limiting toxicities (DLT) occur. However, nowadays the dosing regimen,
which determines the timing of drug administration, is varied in addition to the drug amount itself;
e.g. a weekly or daily schedule. Standard methods such as the Bayesian Logistic Regression Model
do not directly allow for more than one dosing regimen to be evaluated, and hence ad-hoc approaches
like dose re-scaling are used to make dosing regimens comparable. To avoid such ad-hoc approaches,
we propose a new statistical model that uses pharmacokinetic (PK) principles to integrate varying
dosing regimens. We propose to use a latent pseudo-PK, which uses the preplanned dosing regimen.
We complement the pseudo-PK by an effect compartment which admits a delay between the PK and
the actual effect, the occurrence of a DLT. The effect compartment measure is used as exposure mea-
sure and set directly proportional to the instantaneous hazard of the time-to-first DLT event process.
The model is formulated using interpretable parameters which facilitates the specification of priors.
Moreover, we derive from the time-to-event model metrics which enable escalation with overdose con-
trol. In a Monte Carlo simulation study, the proposed model displayed desirable performance in terms
of investigated measures across a range of dose-toxicity profiles including single and varying dosing
regimens. The proposed model is motivated and illustrated by a real-life example. The software to
implement the proposed model (R and Stan code) is publicly available.
Keywords:Phase I dose-escalation trials, multiple dosing regimens, pharmacokinetic models, Stan
1 Introduction
Phase I dose-escalation trials constitute the first step in investigating the safety of potentially promising
drugs in humans.1 In oncology, such trials traditionally focused on identifying the maximum tolerated
dose (MTD) and/or the recommended phase II dose through a series of dose escalation steps. The
almost exclusive focus on safety in oncology is driven by the fact that cytotoxic drugs are generally
most effective at the MTD. While safety is central to all drug therapy, its role in dose selection for
other mechanisms of action is more nuanced.
Dose-escalation trials in oncology traditionally enroll small cohorts of patients who are treated in
cycles. Typically, the estimation of the MTD is based on the toxicity data of the first cycle data only.
The observed toxicities are classified into dose-limiting toxicities (DLT) and non-DLTs. Each time a
cohort finishes its first cycle at a given dose intensity, the available data is assessed to decide how the
trial proceeds. A commonly accepted target for the MTD is to allow for a DLT probability of 33%
per cycle of treatment.2
To facilitate effective and safe learning in the dose escalation trials, adaptive model based ap-
proaches such as the Continual Reassessment Method (CRM)3 or the Bayesian Logistic Regression
Model (BLRM)4,2 are commonly used. Both of these methods predict the toxicity profile for all doses
planned in a given trial, which includes a prediction for already tested and yet untested dose-levels.
These model based assessments are used to guide the dose-escalation trial in order to warrant the
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safety of patients by avoiding unacceptable high risks for DLTs. The BLRM is a two parameter ver-
sion of the CRM which avails of the so-called Escalation-With-Overdose-Control (EWOC)5 principle;
i.e. requires that for a given dose the probability for a DLT must not exceed the maximal admissible
DLT probability by a fixed uncertainty margin. The BLRM has been shown to have good performance
in extensive simulation studies,4 and has been used for many phase I trials including drug combination
trials (see e.g.6,7,8,9). Furthermore, historical data can be incorporated via meta-analytic predictive
(MAP) priors2 to improve predictive performance.
A key limitation of the BLRM is that it cannot naturally take into account differing dosing regimens
(different dosing amounts and frequencies) which are more commonly used in oncology, for example
starting with a weekly dosing regimen and then changing to a daily dosing regimen. Changes in
regimens mean that scaling by dose alone is no longer necessarily a valid assumption because for a
given dose level very different responses may be observed depending on the frequency of administration.
A trivial analogy is that it matters if we drink 3 units of alcohol in 1 hour or over 3 hours. Often,
ad hoc approaches such as dose re-scaling are used in an attempt to account for the regimen effect.
Such ad hoc approaches are always context specific approximation, meaning multiple models are
necessary for multiple regimens and in addition data from different regimens must be discounted due
to the often simplistic non-model based bridging of the available data. This means, the underlying
dosing regimen-DLT relationship needs to be learned repeatedly from a discounted base data set,
which increases the required sample sizes and strongly limits the use of existing data to predict the
dose-toxicity relationship of untested regimens.
A more rational approach to account for dosing regimen is to draw on the theory and practice
underlying pharmacokinetic-pharmacodynamic (PK/PD) models. In particular, we are suggesting
to use PK principles to model the relationship between time-to-first DLTs and the planned dosing
regimen in a model-based approach following the spirit of Cox et al.10 The key point here is to
account for the overall kinetic properties implied by drug input rate of a regimen, drug elimination
from the body of the patient and delays between drug exposure and actual drug effect. Our novel
model, a time-to-event pharmacokinetic model henceforth referred as TITE-PK, requires data on the
exact dosing schedule and adverse event history. TITE-PK includes a latent pseudo-PK based on
the preplanned dosing regimen and is therefore considered like a (time-varying) baseline covariate.
Formally, the latent pseudo-PK process is used to define a time-varying exposure metric, which we use
to construct a time-varying Poisson process describing the DLT event process. TITE-PK assumes that
a given dose input over time, produces a proportional signal that drives the probability of observing
a response subsequent to dosing. This signal decays exponentially similar to drug concentration in a
one compartment model. Similar to PK/PD models, the signals associated with repeated dosing are
superimposed in a manner that accounts for the loss of signal since administration of the previous
dose(s). Systematic delays between the signal and the observed responses are accounted for by a
further exponential function akin to a so-called effect compartment that can be used to account for
delays in the distribution of drug from plasma to the effect site. The instantaneous hazard of the
time-to-first DLT is directly proportional to the pseudo PK signal. Analogous to the monotonicity
assumption in the BLRM, the proportionality constant which drives the Poisson process is constrained
to be strictly positive. Two parameters are required to account for the decay and the delay. Prior
information on all parameters may be included by adopting a Bayesian framework.
The proposed approach builds on the positive experience with the BLRM, but has the added
benefit of allowing changes in dose and dosing regimens to be taken into account in a systematic
manner that draws on the significant positive experience from PK/PD analyses. Note that in the
proposed model, PK analysis and safety analysis are not combined as is done for example by Ursino et
al.11 This simplification is made to ensure the operational applicability of our approach in a realistic
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clinical trial setting. In clinical trials it is often not feasible to obtain reliable PK data in time for
dose-escalation decision meetings. Instead, the model is conditioned on known PK parameters from
previous analyses following the work of Cox et al.10
The main contribution of this paper is to introduce a novel approach, TITE-PK, for analysing
and guiding phase I dose-escalation trials with different dosing regimens. Our approach builds on
experience with the BLRM which has demonstrated the value of the EWOC principle implemented
within a Bayesian framework. The R and Stan code for the implementation of the TITE-PK are
available from Github (https://github.com/gunhanb/TITEPK_code). In Section 2, we describe a
motivating phase I trial example from oncology which investigated daily and weekly dosing regimens.
In Section 3, we review the BLRM and its ad-hoc extensions for combining regimens, and introduce
the proposed TITE-PK model. In Section 4, the BLRM and TITE-PK are applied to the motivating
example. Finally, the performance of both approaches are compared in a simulation study in Section
5. Scenarios involving simple and complex dosing regimens are considered. We close with discussion
and conclusions.
2 Motivating example: Everolimus trial
Everolimus (RAD001) is an oral inhibitor of mammalian target of rapamycin, that is being developed
as an antitumor agent.12 Everolimus is approved by the US FDA to treat various conditions includ-
ing certain types of pancreatic cancer and gastrointestinal cancer,12 and certain type of tuberous
sclerosis.13 Everolimus is also approved to treat transplant rejection.12 Everolimus was included in a
phase Ib trial in combination with standard of care (etoposide and cisplatin chemotherapy) to iden-
tify a feasible dosing regimen in the treatment of small cell lung cancer (ClinicalTrials.gov identifier:
NCT00466466).14 The trial was open-label and multi-centered. Patients were assigned alternately to
either weekly or daily regimens of everolimus in treatment cycles of 21 days. The final data can be
obtained from the supplementary material of Besse et al.14 The dataset is displayed in Table 1. All
DLTs were reported at day 15. The elimination half-life and the absorption rate of everolimus for
cancer patients are reported as 30 (hours) and 2.5 (1/hours), respectively.15 A Bayesian time-to-event
model was used to inform the dose-escalation decisions.16 A dosing regimen of 2.5 mg/day everolimus
was identified as the MTD.
Table 1: Data of the Everolimus trial. The dosing regimens that are used, the doses that are
administered in mg., number of patients, and number of DLTs are given.
Regimen Dose Number Number
(mg) of patients of DLTs
Weekly 20.0 5 0
Weekly 30.0 13 4
Daily 2.5 4 2
Daily 5.0 6 3
We used this trial to compare the performance of the TITE-PK and BLRM methods because: (1)
the trial evaluated two different regimens (weekly and daily dosing), and (2) the large number of DLTs
allow a good assessment on the relative performance of the respective methods.
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3 Methods
In this section, we briefly review the BLRM and an extension of the BLRM which is necessary to
account for the multiple regimens. Subsequently, we describe the proposed TITE-PK model, and its
software implementation. Our primary focus is the application of these methods to phase I dose-
escalation trials with more than one dosing regimen, although we also consider trials with only one
dosing regimen. For simplicity, consider there are two dosing regimens, R1 and R2, and the aim is to
determine the MTD characterized by the dosing amount and the dosing regimen.
3.1 The BLRM
The BLRM is a logistic regression model in the logarithm of a standardized dose. For dose d, the
number of patients with a DLT (rd) in a cohort of size nd are assumed to be binomially distributed
rd ∼ Bin(pid, nd) (1)
with DLT probabilities (pid) and two parameters (α1 and α2)
logit(pid) = log(α1) + α2 log(d/d∗), (2)
where d∗ is the reference dose used for standardization of the dose. At the reference dose the odds of
the DLT are α1. Thus, the reference dose is critical in choosing a prior for α1 and is usually defined
such that the reference dose d∗ is set to the anticipated MTD at which an odds of 1/2 is used as mean
for the α1 prior.
In the absence of relevant historical data, Neuenschwander et al2 suggest the use of weakly in-
formative priors (WIPs) for α1 and α2. Their suggested WIP is a bivariate normal distribution
(log(α1), log(α2)) ∼ N (m,S) with means (m1 = logit(pid∗),m2 = 0), standard deviations (s1 =
2, s2 = 1), and the correlation ρ = 0.
To inform the dose-escalation decisions, the posterior distribution of the DLT probability pid is
used. The DLT probabilities are classified into three categories as follows
(i) pid < 0.16 Underdosing (UD)
(ii) 0.16 ≤ pid < 0.33 Targeted toxicity (TT)
(iii) pid ≥ 0.33 Overdosing (OD)
Escalation or de-escalation decisions are informed using the overdosing probability of dose d,
P (pid ≥ 0.33). The EWOC criteria is fulfilled, if P (pid ≥ 0.33) is smaller than the pre-specified
feasibility bound, a, which was recommended as 0.25 by Babb et al.5 In this paper, we use a = 0.25
throughout the manuscript, unless another value is stated explicitly.
The BLRM does not distinguish in which frequency doses are administered to the patients (for
example weekly dosing frequency or daily dosing frequency), but only the dosing amounts. Hence, an
extension of the BLRM is used to incorporate different dosing regimens in a phase I trial, which we
describe now.
3.1.1 The BLRM MAP
The BLRM with a meta-analytic predictive (MAP) approach17,18 can be used for informing dose-
escalation decisions in a phase I study with more than one dosing regimen. Hereafter we refer this
method as the BLRM MAP. In the BLRM MAP approach, the doses from the first dosing regimen
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(R1) are re-scaled so that two sets of doses from different regimens are comparable. For example,
if R1 is weekly dosing and R2 is daily dosing, the doses from R1 are divided by 7. This ensures
that the respective nominal dose in each regimen results in the same cumulative dose. Then, a meta-
analytic-predictive (MAP) prior is derived using the data of the R1 assuming some between-regimen
heterogeneity for the parameters. The idea is that the data coming from R1 is treated as con-current
data (co-data).19 The degree of heterogeneity depends on the switch between R1 and R2. For instance,
one may assume less heterogeneity for the switch between “twice in a day” to daily compared to a
switch between weekly to daily regimen. Furthermore, it may be desirable to make the MAP prior
more robust for possible unwarranted use of data from R1. To achieve this, the robust MAP prior
(BVNRMAP) can be obtained by mixing the MAP prior (BVNMAP) with the WIP (BVNWIP) as
follows:20,2
BVNRMAP = w × BVNMAP + (1− w)× BVNWIP, (3)
where w is the weight which can be chosen, for example, from the range of 0.5 and 0.9. Neuenschwander
et al2 suggested the use of 0.8, and in this paper we follow their suggestion. After the robust MAP
prior is derived, the BLRM is used to inform dose-escalation decisions. Note, that the BLRM MAP
approach leads to distinct dose-DLT models for each regimen and is difficult to conduct in case data
is generated concurrently for R1 and R2 at the same time.
3.2 The proposed method: TITE-PK
The basic concept in this method is inspired by Cox et al.10 Instead of modelling the number of DLTs
as in the BLRM, the time-to-first DLTs are modeled using a time-varying (non-homogeneous) Poisson
process. A time-varying Poisson process can be defined using the instantaneous hazard function (h(t))
for a DLT occurring at time t as21
h(t) = lim
δt→0+
P (t ≤ T < t+ δt|T ≥ t)
δt
. (4)
The hazard function corresponds to the probability that a patient experiences a DLT in the time
interval (t, t + δt] given that they did not experience a DLT until time t. The hazard is modeled as
a time-dependent function which is directly proportional to an exposure measure of the drug (E(t))
as10
h(t) = β E(t), (5)
where β is the proportionality parameter to estimate. Note that, here, the exposure measure refers to
the drug concentration as in a exposure-response model,22 and the calculation of E(t) will be explained
in Section 3.2.1. Furthermore, if we integrate both sides of Equation (5), we obtain
H(t) = βAUCE(t), (6)
where AUCE(t) is the area under the curve of the exposure measure over time and H(t) is the
cumulative hazard function, respectively.
From the event history analysis,21 we know that the probability density for an event to occur at
time-point t is
f(t) = h(t) exp(−H(t)) (7)
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and the survivor function for the event to occur past some time-point t is given by
S(t) = P (T > t) = exp(−H(t)). (8)
In the following we use Cj to denote the censoring time of patient j. By convention we restrict the
follow-up period for all patients to cycle 1 only. Thus, all patients without a DLT up to the end of
cycle 1 will be censored at the end of cycle 1, Cj = t∗. Long-term DLTs will thus not be considered,
which will be discussed later. Furthermore, we denote with δj an event indicator which is set to 0 for
censored events and 1 for DLT events. The overall likelihood can be written as
L(T,C|β) =
J∏
j=1
f(Tj |β)δj S(Cj |β)(1−δj), (9)
where J is the total number of the patients. Now, we discuss the exposure measure of the drug.
3.2.1 Pseudo-PK model
The proposed exposure model in the TITE-PK model does not rely on measured drug concentration
data, as this data is not routinely available in a form that it may be used directly in the model
to support escalation decisions in a timely manner. For this reason, PK is considered as latent
variable which we refer to as pseudo-PK. The pseudo-PK is used to account for the dosing history
and the expected accumulation in exposure over time that ultimately drive pharmacological responses,
including safety. The main purpose of the pseudo-PK model is to account for the natural “waxing
and waning” of exposure observed after dosing of drug. This pseudo-PK model has a “central”
compartment into which the drug is administered which accounts for drug elimination as a linear first
order process; i.e. the elimination rate is proportional to the amount of drug in the compartment23
dC(t)
dt
= − log(2)
Te
C(t), (10)
where C(t) is the concentration of drug in the central compartment and Te is the elimination half-life.
As the volume of the central compartment cannot be identified for a latent pseudo-PK, we set it by
convention to unity. The elimination half-life Te is assumed to be known from previous analyses and
we will evaluate the sensitivity of the approach to misspecification of the elimination half-life.
To account for delays between the instantaneous drug concentration in the central compartment,
we use a so-called effect compartment23
dCeff(t)
dt
= keff (C(t)− Ceff(t)), (11)
where Ceff(t) is the drug concentration in the effect compartment, and keff is the PK parameter which
governs the delay between the concentration in the central compartment (C(t)) and the concentration
in the effect compartment (Ceff(t)).
The ordinary differential equations (ODEs) (10) and (11) account dosing over time through ad-
ministration into the central compartment. The analytical solution to the ODE system for multiple
doses is obtained through the use of the superposition principle which holds for linear ODE systems
(see e.g.24). This model can account for the natural history of any number of dosing regimens over
time. In order to simplify the notation, we restrict ourselves here to regular dosing regimens which
have a dosing frequency f (in units of 1/h), start at time t = 0h and use the same dose amount d for
all dosing events. With these simplifications (in notation) the solution to the above ODE system is
Ceff(t|d, f) = d
∞∑
i=0
Θ(t− i
f
) keff
keff − log(2)Te
(e−
log(2)
Te
(t− i
f
) − e−keff(t− if )), (12)
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where Θ denotes the Heaviside step function (or unit step function).
To facilitate meaningful interpretation of the parameter β, and hence to help prior specification,
the exposure measure E(t) is obtained by scaling Ceff(t) using a reference regimen including a reference
dose (d∗) and a reference dosing frequency (f∗) at the end of cycle 1 (t∗) such that
E(t|d, f) = Ceff(t|d, f)∫ t∗
0 Ceff(t|d∗, f∗) dt
AUCE(t∗|d∗, f∗) =
∫ t∗
0
E(t|d∗, f∗) dt = 1.
Note that this is analogous to the usage of a reference dose in the BLRM as discussed in Section 3.1.
For illustrative purposes, the calculated C(t), E(t), and AUCE(t) of the Everolimus trial for 20
mg/weekly and 5 mg/daily dosing using different keff values are displayed in Figure 1. Notice that
AUCE(t) of 5 mg/daily at week 3 is 1, since 5 mg/daily is taken as the reference regimen and the
length of cycle 1 is 3 weeks.
3.2.2 Informing dose-escalation decisions
To inform escalation decisions during the phase I trial, TITE-PK uses an adapted EWOC criteria
analogous to the BLRM metric. Hence, the probability that a patient experiences at least one DLT
within the first cycle (shortly the end-of-cycle 1 DLT probability) given the regimen with dose d
and frequency f , P (T ≤ t∗|d, f), is our measure of interest. By using the relationship between
P (T ≤ t∗|d, f) = 1− P (T > t∗|d, f) and combining Equation (8) with (6) it follows that
P (T > t∗|d, f) = exp(−H(t∗|d, f)) =1− P (T ≤ t∗|d, f)
⇔ log(H(t∗|d, f)) = log(− log(1− P (T ≤ t∗|d, f))) = cloglog(P (T ≤ t∗|d, f)). (13)
Since the cumulative hazard H(t|d, f) is set proportional, see Equation (6), to the area under curve
of the exposure metric AUCE(t|d, f) this leads to
cloglog(P (T ≤ t∗|d, f)) = log(β) + log(AUCE(t∗|d, f)). (14)
For the reference regimen with dose d∗ and dosing frequency f∗ the AUC of the exposure measure
up to the reference time-point is unity, AUCE(t∗|d∗, f∗) = 1, such that cloglog(P (T ≤ t∗|d∗, f∗)) =
log(β) holds which highlights the importance of the reference regimen to specify the prior for the
parameter β.
We consider two models, a one-parameter TITE-PK model and a two-parameter TITE-PK model.
In the one-parameter model, the only parameter to estimate is the regression coefficient β, and the
PK parameter keff is assumed to be known. In the two-parameter model, keff is considered unknown.
The elimination half-life Te is assumed to be known for both models.
3.3 Software implementation
The BLRM and the BLRM MAP can be implemented using Markov chain Monte Carlo (MCMC), for
example, via BUGS-variant programs such as WinBUGS25 or JAGS.26 BUGS code for the BLRM
and the Robust MAP are included in the Appendix of Neuenschwander et al4 and the supplementary
material to the paper by Schmidli et al,20 respectively. For our implementations, we use JAGS via the
R2jags R package to generate four parallel chains of 100,000 MCMC samples after a 10,000 iteration
warm-up. To check MCMC convergence, we used the Gelman-Rubin statistics, trace plots and lag 1
sample autocorrelations.
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Figure 1: Illustration of concentration in the central compartment (C(t)), the exposure measure
of the drug (E(t)), and the AUC over exposure measure (AUCE(t)) for 20 mg/weekly and 5
mg/daily regimens of the Everolimus trial, respectively. Reference regimen is 5 mg/daily, and
the length of cycle 1 is 3 weeks. Different keff values, a high value of keff (keff = 2) and a low
value of keff (keff = 0.05), are used to show the influence on the E(t).
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The proposed model TITE-PK is implemented in Stan27 via rstan R package. The corresponding
code for the implementation of the TITE-PK method is available from Github (https://github.
com/gunhanb/TITEPK_code). Four parallel chains of 1,000 MCMC iterations after warm-up of 1,000
iterations are generated. Convergence diagnostics are checked using the Gelman-Rubin statistics and
traceplots. There were no divergences reported for the implementation of the application.
4 Revisiting the Everolimus trial
Returning to the data set described in Section 2, consider the Everolimus trial shown in Table 1.
Firstly, we analyse the data only from the daily regimen using the BLRM, the one-parameter TITE-
PK, and the two-parameter TITE-PK. Secondly, we analyse the data considering both weekly and
daily regimen using the BLRM MAP, one-parameter TITE-PK, and the two-parameter TITE-PK.
Note that although the cohorts of weekly and daily regimen are administered simultaneously in the
Everolimus trial, we analyse the dataset as if the trial is conducted sequentially, specifically daily
regimen after weekly regimen. This is because, we want to compare the proposed method with
the BLRM MAP, which is only applicable for phase I trials involving different regimens conducted
sequentially. The proposed method TITE-PK can be used for phase I trials in which data is generated
concurrently for different regimen at the same time, but we come to this point at the discussion. The
reference regimen is determined using dosing amount of 5 mg (d∗ = 5 mg) and dosing frequency of
24 hours (f∗ = 1/24 1/h). For TITE-PK both models, the elimination half-life is taken as Te = 30
(hours).
To compare the BLRM and TITE-PK models, priors are constructed so that a priori DLT proba-
bilities from BLRM and end-of-cycle 1 DLT probabilities from TITE-PK models are similar. To define
a WIP for BLRM, we choose a bivariate normal prior with following parameters (m1 = logit(pid∗ =
0.175),m2 = 0, s1 = 1.25, s2 = 1, ρ = 0). For TITE-PK models, a normal WIP is chosen such that
log(β) ∼ N (cloglog(P (T ≤ t∗|d∗, f∗) = 0.175), 1.252). For two-parameter TITE-PK, a WIP for the
parameter keff is derived using the cycle length and the absorption rate. Specifically, a log-normal
distribution is setup by matching the inverse of cycle length, 1/504 (1/h), and the absorption rate, 2.5
(1/h) as the 0.025 and 0.975 quantiles, respectively. This gives a log-normal distribution with mean
parameter 0.41 and the standard deviation parameter 0.27. For the one-parameter TITE-PK model,
keff is taken as the mean of the derived WIP for keff. The summaries of a priori DLT probabilities
of the BLRM, the one-parameter TITE-PK, and the two-parameter TITE-PK models are shown in
Figure 2A. Points, thick lines and thin lines correspond to median estimates, the 50% and the 95%
equitailed credible intervals, respectively. Vertical dashed lines (0.16-0.33) are the boundaries of the
targeted toxicity interval. If the upper bound of 50% credible interval of a dose is higher than the 0.33
value, then the overdosing probability of the corresponding dose exceeds the pre-specified feasibility
bound 0.25. Therefore, the corresponding dose is an overdose based on the EWOC criteria. From
Figure 2A, we can see that for all three models, a priori, doses of 7.5 mg and 10 mg are overdoses,
while doses of 2.5 mg and 5 mg are not.
Figure 2B displays the posterior estimates of DLT probabilities, when we only consider daily
regimen data. Results obtained by one parameter TITE-PK and two parameter TITE-PK models
are very similar. To compare those two models, we also calculate approximate leave-one-out cross
validation (LOO) values28 using the loo R package. LOO values of one parameter TITE-PK and two
parameter TITE-PK models are 81.1 (standard error 27.6) and 81.5 (standard error 27.7), respectively.
The difference of the expected log pointwise predictive density of LOO values between one parameter
TITE-PK and two parameter TITE-PK is -0.2 (standard error 0.1). If we compare BLRM and TITE-
PK models, all three methods suggest that all doses are overdoses, meaning that the trial should be
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stopped without any dose declared as the MTD. This seems reasonable, since 2 DLTs observed from
4 patients in 2.5 mg, and 3 DLTs from 6 patients in 5 mg dose.
Figure 2: Everolimus trial: Prior (A), posterior medians daily (B), and weekly + daily (C),
50% equitailed credible intervals (thick lines), and 95% equitailed credible intervals (thin lines)
of daily doses for DLT probabilities obtained by BLRM (BLRM MAP for weekly + daily) and
for end-of-cycle 1 DLT probabilities obtained by one parameter TITE-PK and two parameter
TITE-PK models. “Weekly + Daily” refers that data from both weekly and daily dosing
regimens are included in the analysis, whereas “Daily” means data only from daily dosing
regimen is considered. Vertical dashed lines (0.16-0.33) are the boundaries of the targeted
toxicity interval.
We continue by combining weekly and daily regimen data. We estimate the DLT probabilities of
daily doses but also taking into consideration the data coming from the weekly data. As explained
in Section 3.1.1, to implement BLRM MAP, the doses of weekly regimen, namely 20 mg and 30 mg,
are re-scaled dividing them by 7. The Robust MAP prior is constructed by mixing the MAP prior
and the WIP using the weight of 0.8 (w = 0.8). Finally, the BLRM is fitted and posterior estimates
of DLT probabilities are obtained. On the other hand, our method TITE-PK, naturally, combines
information from different regimens without requiring any ad-hoc method. Figure 2C displays the
estimated posterior summaries of DLT probabilities of daily doses obtained by one parameter and
two parameter TITE-PK and BLRM MAP approaches. As in Figure 2B, two parameter TITE-PK
model did not show any improvement compared to one parameter TITE-PK model in terms of the
LOO estimate. Hence, hereafter we only consider one parameter TITE-PK model, and use TITE-PK
to refer one parameter TITE-PK model.
For both TITE-PK and BLRM MAP, the overdosing probability of dose 2.5 mg/daily is decreased
substantially, namely from 0.49 to 0.27 for BLRM MAP, and from 0.28 to 0.01 for TITE-PK. The
reduction of the overdosing probabilities of 2.5 mg/daily seems reasonable, since in the weekly regimen
data, 0 DLTs occurred from 5 patients in 20 mg/weekly and 4 DLTs occurred from 13 patients in 30
mg/weekly. However, the interval estimates obtained by TITE-PK are shorter, hence more precise
estimates compared to BLRM MAP. Unlike BLRM MAP, TITE-PK suggests that 2.5 mg/daily is not
an overdose, hence it can be declared as the MTD which was the conclusion of the original phase I
trial. Also it must be noted that results of BLRM MAP depends on the choice of the weights which
are used for the construction of the Robust MAP prior. For instance, if we choose the weight of 1.0 for
BVNMAP instead of 0.8, then the overdosing probability of 2.5 mg/daily reduces to 0.20 which is not
an overdose based on the EWOC criteria. It is also worthwhile to point out that conceptually BLRM
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MAP is different in comparison to TITE-PK. The BLRM MAP approach for different regimens is
a two-step approach which establishes two distinct models; one per dosing regimen. The TITE-PK
model instead combines in a model based approach all available information.
As pointed out in Section 3.2.1, by construction of TITE-PK, the elimination half-life Te is treated
as known. To investigate the influence of misspecification of the Te parameter, we fit TITE-PK using
Te ranging from 5 to 50 hours. The timing of all DLTs (in total 9 DLTs) were reported at day 15. To
examine what would be the influence of the timing of DLTs, we also fit TITE-PK to two hypothetical
datasets. Early DLTs dataset and late DLTs dataset are created by changing timing of DLTs from
day 15 to day 1.5 and to day 20.5, respectively. Posterior estimates of DLT probabilities for different
Te values and for different timing of DLTs are shown in Figure 3. The middle plot corresponds to
the original Everolimus trial data. Firstly, the posterior medians and credible intervals obtained by
different Te values look very similar. Note that it is highly probable to not to have a precise estimate
of elimination half-life during a phase I trial, hence these results are reassuring for the practicality of
TITE-PK. Secondly, timing of DLTs have a crucial affect on the posterior estimates, and hence the
overdosing probabilities. Having the same number of DLTs, the earlier the DLT happened, the higher
the overdosing probability of the corresponding dose estimated. This makes sense, since one would
expect the drug is more toxic if DLTs happened earlier than later.
Figure 3: Misspecification of elimination half-life Te and different timing of DLTs. Using
different values of Te, posterior median, 50% and 95% equitailed credible intervals for end-of-
cycle 1 DLT probabilities obtained by TITE-PK for two hypothetical datasets (early DLTs and
late DLTs) and the original Everolimus trial dataset are shown. Early DLTs dataset and late
DLTs dataset are created by changing timing of DLTs from day 15 to day 1.5 and to day 20.5,
respectively. Data from both weekly and daily dosing regimens are included in the analysis.
5 Simulation study
In order to assess the performance of the TITE-PK and to compare with the BLRM under different
true dose-DLT profiles and different regimens, various scenarios are investigated in a simulation study.
5.1 Simulation settings
Simulation study follows the clinical scenario evaluation framework introduced by Benda et al.29
In all scenarios, by mimicking the Everolimus trial, PK parameters are chosen such that Te = 30
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(hours) and log(keff) = 0.41. Weekly doses of 8, 16, 32, 64, 115, 230 (mg/weekly) and daily doses
of 1, 2, 4, 8, 15, 30 (mg/daily) and are considered. Reference dose and reference dosing frequency
are determined using 8 mg (d∗ = 8 mg) and 24 hours (f∗ = 1/24 1/h). Cycle length is taken
as 28 days instead of 21 day as in Everolimus trial, since the former is more common. As in the
Everolimus application, WIPs are constructed so that a priori DLT probabilities of BLRM and TITE-
PK are similar. For BLRM, we choose a BVN prior with following parameters: (m1 = logit(pid∗ =
0.175),m2 = 0, s1 = 2, s2 = 1, ρ = 0). For TITE-PK model, a normal WIP is chosen such that log(β)
∼ N (cloglog(P (T ≤ t∗|d∗, f∗) = 0.175), 1.752). Although the choice of prior can have an influence
on posterior estimates for a Bayesian phase I design, we did not consider to vary the priors. This is
because our aim is to compare the BLRM and TITE-PK given that they have a priori similar DLT
probabilities for all doses. However, we recommend varying priors as part of sensitivity analyses when
TITE-PK is used for an application as is the case with other Bayesian phase I models.
For the first setting of scenarios, six different dose-DLT profiles with only daily dosing are con-
sidered as shown in Figure 4B. Scenario 3 is the basis and equals to the mean of a priori medians
of the TITE-PK and BLRM. DLT probabilities of Scenario 1 and 2 are 0.25 and 0.75 of the DLT
probabilities of Scenario 3, respectively. Thus Scenario 1 and 2 have lower toxicity compared to the
basis (Scenario 3). Similarly, Scenario 4 and 5 are 1.25 and 1.75 of Scenario 5, respectively, hence
more toxic scenarios. Finally, Scenario 6 is an extreme scenario that is highly inconsistent with the
prior, and it is taken from Babb et al.5 In the second and third set of scenarios, we consider switching
regimen scenarios. We assumed that after the MTD declaration of the weekly dosing, daily dosing is
administered to the patients and then MTD is declared for the daily dosing. For the daily dosing, the
scenarios illustrated in Figure 4B are used. Figure 4A displays the true dose-DLT profiles used in the
weekly dosing scenarios and they are calculated using same procedure with daily dosing scenarios. In
the second simulation set of scenarios, we consider the same true dose-DLT profiles between different
regimens. For example, a trial is started with weekly dosing of Scenario 3, after MTD declaration,
it is switched to the daily dosing of Scenario 3. In third set of scenarios, we consider the situations
when there is conflict of true dose-DLT profiles between weekly and daily regimens. For instance, in
the weekly regimen, Scenario 2 is used, and then switched to the daily dosing of Scenario 3.
The data generation processes for BLRM and TITE-PK are different, since the former uses a
binomial distribution whereas the latter uses a time-varying Poisson process. Hence, we run the
simulations separately for two methods. For BLRM, specification of the true dose-DLT profiles are
enough to simulate data. But for TITE-PK, we also need to specify the cycle length as well as the
PK parameters Te and keff. For both TITE-PK and BLRM, data for 1,000 trials were generated.
The following criteria for the simulations are taken from Neuenschwander et al.2 Sample sizes were
randomly chosen cohorts of size 3-6. The maximum number of patients per trial was set to 60. The
trial was stopped when one of the following criteria were met:
(i) At least six patients have been treated at the recommended MTD.
(ii) The MTD dose satisfies one of the following conditions:
• The probability of targeted toxicity at recommended MTD dose exceeds 50%.
• A minimum of 21 patients have already been treated in the trial.
5.2 Results
To assess the performance of the BLRM and TITE-PK in the simulations, we used six measures which
are demonstrated in Table 2. Performance measures obtained by TITE-PK and BLRM for the first
set of scenarios (only daily dosing) are shown in Figure 5. For all six scenarios, the percentage of
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Figure 4: Dose-DLT profiles of different scenarios for weekly dosing (A) and for daily dosing
(B). The shades are increasing by the toxicity of the scenario.
Table 2: Performance measures assessed in the simulation study.
Measures Explanation
I Percentage of patients receiving an underdose.
II Percentage of patients receiving a dose that is in the targeted toxicity interval.
III Percentage of patients receiving an overdose.
IV Probability that recommended MTD is an underdose.
V Probability that recommended MTD is in the targeted toxicity interval.
VI Probability that recommended MTD is an overdose.
Stopped Probability that trial is stopped without recommending MTD.
AveN Average number of patients dosed.
AveDLT Average number of DLTs observed.
trials with MTD identified in targeted toxicity (TT) region (correctly identifying MTD) are higher
in TITE-PK compared to the BLRM. On the other hand, for scenarios 2, 4, and 5, the percentage
of trials with an overdose identified MTD is higher in TITE-PK compared to BLRM, although only
scenario 4 can be seen as problematic (14.3% in TITE-PK vs 7.1% in BLRM). However, the percentage
of patients receiving an overdose is not extremely higher in TITE-PK in comparison to BLRM (10%
in TITE-PK vs 8.3% in BLRM). Furthermore, to improve these results, we consider TITE-PK using
a modified EWOC, namely using pre-specified feasibility bound a = 0.20 instead of a = 0.25. Note
that reducing the feasibility bound results the conservative dose-escalation decisions, that is reducing
the percentage of trials with an overdose identified MTD but also reducing the percentage of trials
with correctly identified MTD. The percentage of trials with correctly identified MTD obtained by
TITE-PK using a = 0.20 is decreased to 11.1%, while in all scenarios, TITE-PK outperforms BLRM
in terms of this metric. Scenario 6 needs special consideration. For this very toxic scenario, while the
measure for correctly identifying MTD are higher in both TITE-PK methods in comparison to the
BLRM, the percentage of patients treated at overdoses is also considerably lower compared to BLRM
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(26.6% in TITE-PK using a = 0.20 vs 35.8% in BLRM). What is more, the percentage of patients
receiving an overdose obtained by BLRM is higher compared to both TITE-PK using a = 0.25 and
TITE-PK using a = 0.20. In terms of average number of DLTs and average number of sample sizes,
BLRM and TITE-PK methods give similar results, although latter is slightly higher.
Figure 5: Performance measures for the first set of scenarios (only daily dosing regimens).
Three methods are considered: BLRM, TITE-PK, and TITE-PK using a decreased pre-specified
feasibility bound (a = 0.20). Description of scenarios are given in the main text.
Now, we consider the second set of the scenarios, switching regimen scenarios with no conflict of
true dose-DLT profiles of weekly and daily regimens. Performance measures of TITE-PK and BLRM
MAP are shown in Figure 6. Firstly, we can compare both methods to their performances for the
first set of scenarios as shown in Figure 5. It can be clearly seen that for all measures, TITE-PK
is improved. For example, the percentage of trials with an overdose identified MTD of Scenario 4
now reduces to 12.1% from 14.1%. And the percentage of trials with correctly identified MTD of
Scenario 4 increases to 71.3% from 55%. Although in many measures BLRM is also improved, there
are some measures in which it’s performance are getting worse, for example the percentage of trials
with correctly identified MTD of Scenario 5 reduces from 29.5% to 21.4%. Most importantly, if we
compare BLRM MAP and TITE-PK, it can be easily seen that TITE-PK outperforms BLRM MAP
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in many measures especially for correctly identifying MTDs.
Figure 6: Performance measures for the second set of scenarios, switching regimen scenarios
with no conflict of true dose-DLT profiles of weekly and daily regimens. Two methods are
considered: TITE-PK and BLRM MAP. X axis values, for example Sc. 1 and Sc. 1,
refers to starting with weekly regimen of Scenario 1, then continue with daily regimen of
Scenario 1. Description of scenarios are given in the main text.
Lastly, we consider the third set of the scenarios, switching regimen scenarios with conflict of
true dose-DLT profiles of weekly and daily regimens. Performance measures of TITE-PK and BLRM
MAP are shown in Figure 7. Firstly, we can notice that TITE-PK outperforms BLRM MAP in
all considered scenarios in terms of the percentage of trials with correctly identified MTD. For the
fifth scenario (starting with with weekly regimen of Scenario 4, then continue with daily regimen of
Scenario 1: Sc. 4 and Sc. 1), the difference is 40%, for example. For the percentage of trials with
an overdose identified MTD, we see that TITE-PK has lower or equal value compared to BLRM MAP
except the third scenario (Sc. 3 and Sc. 4). Note that here we consider the measures of daily
regimen of Scenario 4, hence we can compare these results to Scenario 4 of the first set of scenarios to
see the influence of the inclusion of the weekly regimen of Scenario 3. In the first set of the scenarios,
the percentage of trials with an overdose identified MTD of TITE-PK for Scenario 4 was 14.1%, and
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now it increases to 21.5%. On the other hand, the percentage of trials with an overdose identified
MTD of BLRM MAP is only slightly increased when we compare the first set and third set of scenarios
for Scenario 4, from 7.1% to 8.5%. However, the percentage of patients receiving an overdose obtained
by TITE-PK is not unacceptably high in compared to the BLRM (11.2% in TITE-PK vs 6.7% in
BLRM). Note that the difference of these scenarios compared to previous ones is that the assumption
that the end-of-cycle 1 DLT probability is increasing with higher AUC of the exposure of the drug
is violated. This is analogous to the monotonicity assumption of the BLRM. For example, in the
third scenario (starting with with weekly regimen of Scenario 3, then continue with daily regimen of
Scenario 5: Sc. 3 and Sc. 5), true DLT probability of dose 32 mg/weekly (0.10) is smaller than
true DLT probability of dose 4 mg/daily (0.15), while AUC(t∗) of dose 32 mg/weekly is bigger than
AUC(t∗) of dose 4 mg/daily. This assumption is more relevant for TITE-PK than BLRM-MAP, since
in the latter, data from the weekly regimen is used to construct the prior, but not used as data.
6 Discussion and Conclusion
We propose a Bayesian adaptive model, TITE-PK, to support design, analysis and guidance of phase I
dose-escalation trials, where the drug is administered by different dosing regimens and dosing decisions
are determined by dose limiting toxicities. TITE-PK preserves the advantages of the BLRM including
interpretable parameters, and being able to use the EWOC criteria. It uses PK principles to combine
different dosing regimens in a model-based approach. A real application involving weekly and daily
dosing is used to show the usage of TITE-PK. Moreover, we have demonstrated by means of simulations
that TITE-PK shows better performance in terms of the investigated measures compared to BLRM
for single regimen scenarios and compared to BLRM MAP for combining different regimens in realistic
scenarios.
We considered two models, one parameter TITE-PK model and two parameter TITE-PK model.
The second model has the extra parameter of keff which governs a possible delay between the putative
concentration in the central compartment and manifestation of effect. Note, in this case it also accounts
for the delay between the administration and the manifestation of the putative concentration. In the
Everolimus trial, posterior estimates were not changed when we used the two parameter TITE-PK
model, also the estimated leave-one-out cross validation values were not improved. Hence, we suggest
the usage of one parameter TITE-PK model which is computationally less expensive. An advantage of
using time-to-first DLTs as in TITE-PK instead of only numbers of DLTs as in BLRM is that censored
patients can also be included in the analysis. There are some suggested time to event models for
phase I trials, for example TITE-CRM16 which, additionally, models long term DLTs not only DLTs
occurring in the first cycle as in TITE-PK.30 TITE-PK can be extended to also incorporate long term
DLTs which requires the modelling of the recurrent DLTs, and two parameter TITE-PK model could
be more useful for such long-term safety analysis.
In the simulation study, we only considered the scenarios when different regimens are administered
to the cohort of patients sequentially. That is, the MTD is estimated for the first regimen (R1), then
the second regimen (R2) is administered to the patients, finally the MTD for the second regimen is
estimated. As an alternative design, the data can be generated concurrently for R1 and R2 at the
same time. TITE-PK can be used to inform dose-escalation decisions for both designs. However,
we did not investigate the latter design scenarios, since we want to compare the TITE-PK with the
BLRM MAP, which is only applicable for the former design.
We have used a linear PK model for the pseudo-PK to calculate the exposure measure of the
drug. This implies that the constructed exposure metric is proportional to the administered dose
which extends to the key metric of the model, the end-of-cycle 1 DLT probability. When there is
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Figure 7: Performance measures for the third set of scenarios, switching regimen scenarios with
conflict of true dose-DLT profiles of weekly and daily regimens. Two methods are considered:
TITE-PK and BLRM MAP. X axis values, for example Sc. 2 and Sc. 3, refers to starting
with weekly regimen of Scenario 2, then continue with daily regimen of Scenario 3. Description
of scenarios are given in the main text.
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a clear conflict in dose-DLT profiles between different regimens, this assumption can be seen as a
limitation of TITE-PK. To relax this assumption, one can consider more complicated PK models
including a non-linear PK model which may not have an analytical solution. Such extensions may be
implemented in Stan which has a built-in differential equation solver. However, more complicated
modelling approaches always need to be calibrated well given the sparseness of the phase I dose-
escalation data sets. Alternatively, one can consider an ad-hoc extension of one parameter TITE-PK
model. For instance, similar to the idea of power model,31 a pseudo-dose such as ( dd∗ )γ can be used
instead of dose d in the model which may be helpful to relax the linear PK assumption.
When relevant historical information or data from a different study population exists, it is desirable
to include such information in the analysis of the phase I trial, for example using a MAP prior. Since
TITE-PK is parametrized by mimicking the interpretable parameters of the BLRM, it can be also
extended to use a MAP approach like the BLRM. A key strength of the TITE-PK approach is it’s
ability to integrate the data from different dosing regimens in a model based approach. This makes
ad-hoc approaches used for the BLRM obsolete which reduces the need for strong discounting of
historical data from different regimens. However, discounting may still be needed to account for other
sources of heterogeneity in the data under consideration.
Another crucial aspect of the methods for phase I trials is the ability to analyse the combination
of drugs. Although, we only consider the single agent case here, it is possible to extend TITE-PK
to analyse drug combinations which is complicated by the need to model possible drug interactions.
Moreover, we only considered the fixed feasibility bound to use EWOC, that is a dose is considered an
overdose if the overdosing probability of a dose exceeds a fixed bound. However, one can also consider
varying feasibility bounds as suggested by Wheeler et al.32
In summary, we expect that with TITE-PK the available historical data can be used more efficiently
and that phase I trials can more flexibly explore dosing regimens in dose-escalation trials. This is
achieved through the use of pharmacokinetic principles in the TITE-PK model.
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